Recital 12, Commission Regulation (EU) No 384/2010 of 5 May 2010 on the authorisation and refusal of…

In forcesince 5 May 2010

Following an application from Cambridge Theranostics Ltd., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lycopene-whey complex on risk of atherosclerotic plaques (Question No EFSA-Q-2008-703) [The EFSA Journal (2009) 1179, 1-10.]. The claim proposed by the applicant was worded as follows: ‘Lycopene-whey complex prevents oxidative damage of plasma lipoproteins, which reduces the build up of arterial plaques and reduces the risk of heart disease, stroke and other clinical complications of atherosclerosis’.